Intellia’s CRISPR Cure: Phase 3 Results Offer Hope for 'Functional Healing'

We are witnessing the end of "managing" chronic genetic conditions. This February, Intellia Therapeutics released long-awaited Phase 3 trial data for its in-vivo CRISPR treatment. The results point toward a "functional cure"—a single treatment that permanently corrects the genetic defect responsible for hereditary angioedema.

The Era of One-and-Done

This treatment works by directly editing the genes inside the patient's liver, demonstrating that gene editing is no longer a sci-fi concept but a scalable medical reality for 2026.

One Shot Cure? Phase 3 Data

"This is the first time we've seen a therapeutic effect this profound from a single dose of a gene editor," said a noted biotechnologist. "The door is now wide open for treating dozens of other liver-based genetic diseases."